Berger, Marc Moritz, Peter H. Hackett, and Peter Bärtsch. No relevant analogy between COVID-19 and acute mountain sickness. High Alt Med Biol. 21:315–318, 2020.—Clinicians and scientists have suggested therapies for coronavirus disease-19 (COVID-19) that are known to be effective for other medical conditions. A recent publication suggests that pathophysiological mechanisms underlying acute mountain sickness (a syndrome of nonspecific neurological symptoms typically experienced by nonacclimatized individuals at altitudes >2500 m) may overlap with the mechanisms causing COVID-19. In this short review, we briefly evaluate this mistaken analogy and demonstrate that this concept is not supported by scientific evidence.
Get full access to this article
View all access options for this article.
References
1.
AckermannM, VerledenSE, KuehnelM, HaverichA, WelteT, LaengerF, VanstapelA, WerleinC, StarkH, TzankovA, LiWW, LiVW, MentzerSJ, and JonigkD. (2020). Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in COVID-19. N Engl J Med, 383:120–128.
2.
BartschP, BaileyDM, BergerMM, KnauthM, and BaumgartnerRW. (2004). Acute mountain sickness: Controversies and advances. High Alt Med Biol, 5:110–124.
3.
BartschP, MaggioriniM, RitterM, NotiC, VockP, and OelzO. (1991). Prevention of high-altitude pulmonary edema by nifedipine. N Engl J Med, 325:1284–1289.
4.
BartschP, and SwensonER. (2013). Clinical practice: Acute high-altitude illnesses. N Engl J Med, 368:2294–2302.
5.
BartschP, SwensonER, PaulA, JulgB, and HohenhausE. (2002). Hypoxic ventilatory response, ventilation, gas exchange, and fluid balance in acute mountain sickness. High Alt Med Biol, 3:361–376.
6.
BergerMM, MacholzF, SarebanM, SchmidtP, FriedS, DanklD, NiebauerJ, BartschP, and MairbaurlH. (2017). Inhaled budesonide does not prevent acute mountain sickness after rapid ascent to 4559 m. Eur Respir J, 50:1700982.
7.
BergerMM, SarebanM, and BartschP. (2019). Acute mountain sickness: Do different time courses point to different pathophysiologic mechanisms?. J Appl Physiol (1985), 128:952–959.
8.
BoosCJ, WoodsDR, VariasA, BiscochoS, HeseltineP, and MellorAJ. (2016). High altitude and acute mountain sickness and changes in circulating endothelin-1, interleukin-6, and interleukin-17a. High Alt Med Biol, 17:25–31.
9.
ConnorsJM, and LevyJH. (2020). COVID-19 and its implications for thrombosis and anticoagulation. Blood, 135:2033–2040.
DehnertC, LuksAM, SchendlerG, MenoldE, BergerMM, MairbaurlH, FaoroV, BaileyDM, CastellC, HahnG, VockP, SwensonER, and BartschP. (2010). No evidence for interstitial lung oedema by extensive pulmonary function testing at 4,559 m. Eur Respir J, 35:812–820.
12.
DekkerMCJ, WilsonMH, and HowlettWP. (2019). Mountain neurology. Pract Neurol, 19:404–411.
13.
DevauxCA, RolainJM, and RaoultD. (2020). ACE2 receptor polymorphism: Susceptibility to SARS-CoV-2, hypertension, multi-organ failure, and COVID-19 disease outcome. J Microbiol Immunol Infect, 53:425–435.
14.
HackettPH, and RoachRC. (2001). High-altitude illness. N Engl J Med, 345:107–114.
15.
HackettPH, RoachRC, WoodRA, FoutchRG, MeehanRT, RennieD, and MillsWJJr. (1988). Dexamethasone for prevention and treatment of acute mountain sickness. Aviat Space Environ Med, 59:950–954.
16.
HackettPH, YarnellPR, HillR, ReynardK, HeitJ, and McCormickJ. (1998). High-altitude cerebral edema evaluated with magnetic resonance imaging: Clinical correlation and pathophysiology. JAMA, 280:1920–1925.
17.
HartmannG, TschopM, FischerR, BidlingmaierC, RieplR, TschopK, HautmannH, EndresS, and ToepferM. (2000). High altitude increases circulating interleukin-6, interleukin-1 receptor antagonist and C-reactive protein. Cytokine, 12:246–252.
18.
HeoK, KangJK, ChoiCM, LeeMS, NohKW, and KimSB. (2014). Prophylactic effect of erythropoietin injection to prevent acute mountain sickness: An open-label randomized controlled trial. J Korean Med Sci, 29:416–422.
19.
HonigmanB, TheisMK, Koziol-McLainJ, RoachR, YipR, HoustonC, MooreLG, and PearceP. (1993). Acute mountain sickness in a general tourist population at moderate altitudes. Ann Intern Med, 118:587–592.
20.
HuB, HuangS, and YinL. (2020). The cytokine storm and COVID-19. J Med Virol [Epub ahead of print]; DOI: 10.1002/jmv.26232.
21.
JeongSK, ChoYI, DueyM, and RosensonRS. (2010). Cardiovascular risks of anemia correction with erythrocyte stimulating agents: Should blood viscosity be monitored for risk assessment?. Cardiovasc Drugs Ther, 24:151–160.
22.
JohnsonTS, RockPB, FulcoCS, TradLA, SparkRF, and MaherJT. (1984). Prevention of acute mountain sickness by dexamethasone. N Engl J Med, 310:683–686.
23.
JohnsonTS, RockPB, YoungJB, FulcoCS, and TradLA. (1988). Hemodynamic and sympathoadrenal responses to altitude in humans: Effect of dexamethasone. Aviat Space Environ Med, 59:208–212.
24.
JulianCG, SubudhiAW, WilsonMJ, DimmenAC, PechaT, and RoachRC. (2011). Acute mountain sickness, inflammation, and permeability: New insights from a blood biomarker study. J Appl Physiol (1985), 111:392–399.
25.
KlegerGR, BartschP, VockP, HeiligB, RobertsLJ, 2nd, and BallmerPE. (1996). Evidence against an increase in capillary permeability in subjects exposed to high altitude. J Appl Physiol (1985), 81:1917–1923.
26.
LevineBD, YoshimuraK, KobayashiT, FukushimaM, ShibamotoT, and UedaG. (1989). Dexamethasone in the treatment of acute mountain sickness. N Engl J Med, 321:1707–1713.
27.
LiX, and MaX. (2020). Acute respiratory failure in COVID-19: Is it “typical” ARDS? Crit Care 24:198.
28.
LipmanGS, PomeranzD, BurnsP, PhillipsC, CheffersM, EvansK, JurkiewiczC, JuulN, and HackettP. (2017). Budesonide versus acetazolamide for prevention of acute mountain sickness. Am J Med 131:200.e209–200.e216.
29.
LuksAM, FreerL, GrissomCK, McIntoshSE, SchoeneRB, SwensonER, and HackettPH. (2020). COVID-19 lung injury is not high altitude pulmonary edema. High Alt Med Biol, 21:192–193.
30.
LuksAM, and SwensonER. (2020). COVID-19 lung injury and high altitude pulmonary edema: A false equation with dangerous implications. Ann Am Thorac Soc, 17:918–921.
31.
LundebergJ, FeinerJR, SchoberA, SallJW, EilersH, and BicklerPE. (2018). Increased cytokines at high altitude: Lack of effect of ibuprofen on acute mountain sickness, physiological variables, or cytokine levels. High Alt Med Biol, 19:249–258.
32.
MacInnisMJ, and KoehleMS. (2016). Evidence for and against genetic predispositions to acute and chronic altitude illnesses. High Alt Med Biol, 17:281–293.
33.
MaggioriniM, Brunner-La RoccaHP, PethS, FischlerM, BohmT, BernheimA, KienckeS, BlochKE, DehnertC, NaeijeR, LehmannT, BartschP, and MairbaurlH. (2006). Both tadalafil and dexamethasone may reduce the incidence of high-altitude pulmonary edema: A randomized trial. Ann Intern Med, 145:497–506.
34.
MaggioriniM, MelotC, PierreS, PfeifferF, GreveI, SartoriC, LeporiM, HauserM, ScherrerU, and NaeijeR. (2001). High-altitude pulmonary edema is initially caused by an increase in capillary pressure. Circulation, 103:2078–2083.
35.
Recovery Collaborative Group; HorbyP, LimWS, EmbersonJR, MafhamM, BellJL, LinsellL, StaplinN, BrightlingC, UstianowskiA, ElmahiE, PrudonB, GreenC, FeltonT, ChadwickD, RegeK, FeganC, ChappellLC, FaustSN, JakiT, JefferyK, MontgomeryA, RowanK, JuszczakE, BaillieJK, HaynesR, LandrayMJ. (2020). Dexamethasone in hospitalized patients with COVID-19—Preliminary report. N Engl J Med [Epub ahead of print]; DOI: 10.1056/NEJMoa2021436.
36.
RichaletJP, LarmignatP, PoitrineE, LetournelM, and Canoui-PoitrineF. (2012). Physiological risk factors for severe high-altitude illness: A prospective cohort study. Am J Respir Crit Care Med, 185:192–198.
37.
RoachRC, HackettPH, OelzO, BartschP, LuksAM, MacInnisMJ, BaillieJK, and CommitteeLLASC. (2018). The 2018 Lake Louise acute mountain sickness score. High Alt Med Biol, 19:4–6.
38.
Sampaio Rocha-FilhoPA, and VossL. (2020). Persistent headache and persistent anosmia associated with COVID-19. Headache, 60:1797–1799.
39.
SchneiderM, BernaschD, WeymannJ, HolleR, and BartschP. (2002). Acute mountain sickness: Influence of susceptibility, preexposure, and ascent rate. Med Sci Sports Exerc, 34:1886–1891.
40.
SchoeneRB, SwensonER, PizzoCJ, HackettPH, RoachRC, MillsWJJr., HendersonWRJr., and MartinTR. (1988). The lung at high altitude: Bronchoalveolar lavage in acute mountain sickness and pulmonary edema. J Appl Physiol (1985), 64:2605–2613.
41.
SennO, ClarenbachCF, FischlerM, ThalmannR, Brunner-La RoccaH, EggerP, MaggioriniM, and BlochKE. (2006). Do changes in lung function predict high-altitude pulmonary edema at an early stage?. Med Sci Sports Exerc, 38:1565–1570.
42.
SolaimanzadehI. (2020). Acetazolamide, nifedipine and phosphodiesterase inhibitors: Rationale for their utilization as adjunctive countermeasures in the treatment of coronavirus disease 2019 (COVID-19). Cureus, 12:e7343.
43.
SolizJ, Schneider-GasserEM, Arias-ReyesC, Aliaga-RaduanF, Poma-MachicaoL, Zubieta-CallejaG, FuruyaWI, Trevizan-BauP, DhingraRR, and DutschmannM. (2020). Coping with hypoxemia: Could erythropoietin (EPO) be an adjuvant treatment of COVID-19? Respir Physiol Neurobiol 279:103476.
44.
StrapazzonG, HiltyMP, BouzatP, PrataliL, BruggerH, and RauchS. (2020). To compare the incomparable: COVID-19 pneumonia and high altitude disease. Eur Respir J, 55:2001362.
45.
SwensonER, MacDonaldA, VatheuerM, MaksC, TreadwellA, AllenR, and SchoeneRB. (1997). Acute mountain sickness is not altered by a high carbohydrate diet nor associated with elevated circulating cytokines. Aviat Space Environ Med, 68:499–503.
46.
TolksdorfK, BudaS, SchulerE, WielerLH, and HaasW. (2020). Influenza-associated pneumonia as reference to assess seriousness of coronavirus disease (COVID-19). Euro Surveill, 25:2000258.
47.
WangC, JiangH, DuanJ, ChenJ, WangQ, LiuX, and WangC. (2018). Exploration of acute phase proteins and inflammatory cytokines in early stage diagnosis of acute mountain sickness. High Alt Med Biol, 19:170–177.
48.
WichmannD, SperhakeJP, LutgehetmannM, SteurerS, EdlerC, HeinemannA, HeinrichF, MushumbaH, KniepI, SchroderAS, BurdelskiC, de HeerG, NierhausA, FringsD, PfefferleS, BeckerH, Bredereke-WiedlingH, de WeerthA, PaschenHR, Sheikhzadeh-EggersS, StangA, SchmiedelS, BokemeyerC, AddoMM, AepfelbacherM, PüschelK, KlugeS. (2020). Autopsy findings and venous thromboembolism in patients with COVID-19: A prospective cohort study. Ann Intern Med, 173:268–277.
49.
WilsonMH, NewmanS, and ImrayCH. (2009). The cerebral effects of ascent to high altitudes. Lancet Neurol, 8:175–191.
50.
WilsonMH, WrightA, and ImrayCH. (2014). Intracranial pressure at altitude. High Alt Med Biol, 15:123–132.
51.
ZhouF, YuT, DuR, FanG, LiuY, LiuZ, XiangJ, WangY, SongB, GuX, GuanL, WeiY, LiH, WuX, XuJ, TuS, ZhangY, ChenH, and CaoB. (2020). Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study. Lancet, 395:1054–1062.
